Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases
3.2.1.2 Advancements in drug delivery technologies
3.2.1.3 Government support and funding
3.2.1.4 Rapid expansion of the biopharmaceutical industry
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory scenario
3.2.2.2 High development costs
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Kits
5.2.1 Ionizable lipids
5.2.2 PEGylated lipids
5.2.3 Sterol lipids
5.2.4 Neutral phospholipids
5.3 Reagents
5.4 Other products
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Therapeutics
6.3 Research
Chapter 7 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Cancer
7.3 Infectious diseases
7.4 Blood diseases
7.5 Other indications
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Pharmaceutical & biotechnology companies
8.3 Academic & research institutes
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Netherlands
9.3.6 Italy
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Biopharma PEG Scientific Inc.
10.2 BroadPharm
10.3 CordenPharma
10.4 Creative Biolabs.
10.5 Croda International Plc
10.6 Echelon Biosciences
10.7 Merck KGaA
10.8 NOF Corporation
10.9 Polysciences, Inc.
10.10 Tebubio
